A phase 3 randomised clinical trial published in JAMA has challenged the assumption that tumour debulking improves outcomes in patients with multiorgan metastatic colorectal cancer (mCRC), finding no overall survival benefit when local tumour reduction was added to standard first-line chemotherapy.
The ORCHESTRA trial showed that combining tumour debulking with palliative systemic therapy did not significantly improve either overall survival or progression-free survival compared with chemotherapy alone, but it did increase serious adverse events. The findings suggest that routine use of debulking in this setting may expose patients to greater toxicity without meaningful clinical benefit.
Researchers conducted the ORCHESTRA trial, an open-label, phase 3 randomised clinical trial involving 382 patients with multiorgan metastatic colorectal cancer whose tumours were considered amenable to at least 80% debulking before first-line palliative chemotherapy.
All patients initially received standard induction chemotherapy. Those with stable disease or response were then randomised to continue chemotherapy alone or receive chemotherapy plus local tumour debulking, including surgery and/or thermal ablation. The primary endpoint was overall survival.
Key findings
- Median overall survival was 30.0 months in the chemotherapy plus debulking group versus 27.5 months in the chemotherapy-alone group, with no significant improvement in overall survival (adjusted HR 0.88; 95% CI, 0.70–1.10; P = .26).
- Median progression-free survival was 10.5 months versus 10.4 months, respectively, with no statistically significant difference between groups (adjusted HR 0.83; 95% CI, 0.67–1.02; P = .08).
- Serious adverse events were more common in the debulking arm, occurring in 53% of patients compared with 39% in the chemotherapy-alone group (P = .006).
Clinical implications
Aggressive local treatment strategies such as metastasectomy and ablation have an established role in carefully selected patients with limited metastatic disease. However, these results suggest that extending this approach to patients with widespread multiorgan metastatic disease does not provide the same benefit.
The study reinforces the importance of prospective randomised trials before adopting intensive local therapies more broadly, particularly when these interventions may increase toxicity and delay systemic treatment.
For routine practice, the findings do not support tumour debulking as a standard addition to first-line chemotherapy in patients with multiorgan mCRC, outside carefully selected or trial-based settings.
Paper: Gootjes EC, Bakkerus L, Adhin AA, et al. Tumor Debulking in Combination With Chemotherapy in Multiorgan Metastatic Colorectal Cancer: The ORCHESTRA Randomized Clinical Trial. JAMA. 2026;335(15):1311–1320. doi:10.1001/jama.2026.1929 Access online here.
